Printer Friendly

Statement by Sybil Niden Goldrich, Command Trust Network on FDA Panel Tentatively Set for Silicone Gel Breast Implants in April 2005.

LOS ANGELES -- Goldrich is responding to announcements today by the Mentor and Inamed Corporations that the FDA has tentatively set a panel date to review silicone gel breast implants. Inamed also announced that it had submitted its documentation for approval of a new type of cohesive gel silicone breast implant.

I am personally appalled that the FDA would announce that it was taking this controversial device to panel in the midst of the Vioxx scare. Broken breast implants have mutilated many tens of thousands of women specifically because the review process at the FDA better accommodates industry than patient health. Breast implants are, quite simply, the Vioxx of medical device industry.

Last year, the agency had an attack of good sense and called for stringent additional research to examine the high product failure problems with breast implants. Yet we have not heard one word about any new research, or about new standards for research. If the FDA goes to panel in April, it will be reviewing a product without having set the standards for that review - clearly, once again putting the cart before the horse and the needs of industry before the health needs of American women.

The Inamed submission for consideration of a new cohesive silicone gel implant further underscores this cozy industry relationship. This device has been in clinical trials for barely two years. We know from FDA's own research that the latency period for harm from silicone breast implants is seven to ten years. Yet the manufacturers seem to believe the agency will take their submission seriously based on just a few years of clinical trial data.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 6, 2004
Words:270
Previous Article:Golden Goose Resources Inc.: Private Placement.
Next Article:Benvest Capital: Closing of CMN International Inc. Transaction.


Related Articles
Congress urged to limit court secrecy.
A confederacy of boobs.
AVAILABILITY OF IMPLANTS.
FDA study shows silicone breast implants rupture more than previously thought.
LIFESTYLE FACTORS MAY CONTRIBUTE TO BREAST-IMPLANT RISK, STUDY SAYS.
JUDGE OUSTS CLAIMANTS' LAWYERS IN DOW BREAST IMPLANT LAWSUIT.
Flash flood. (Letters).
FDA MAY LIFT BAN ON SILICONE BREAST IMPLANTS TRACKING RECIPIENTS' HEALTH FOR 10 YEARS RECOMMENDED.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters